🇺🇸 US Stock Screener ← Switch market ⚡ HerAI

Aldeyra Therapeutics, Inc. ALDX R2KPHARMA

Healthcare · Biotechnology · United States
Financial distress score 50/100 (Weak) — see indicators →
https://www.aldeyra.com
Company Profile ↓
$0.65
-87.90% 1Y
Mkt Cap$39.21M
P/E-1.71
P/B1.46
52W High$5.89
52W Low$0.64
Book Value$0.63
EPS (TTM)$-0.38

Company Overview

Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa. The company also develops ADX-629, an orally administered RASP modulator that is in Phase 2 clinical trials for the treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication. In addition, it develops preclinical RASP platforms, including ADX 248, ADX 246, and other novel RASP modulators for the treatment of various diseases associated with RASP. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.

Why Investors Should Care

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.38.

Growth & Price Performance

Stock Price Performance

1 Year:-87.90%
6 Months:-58.08%
3 Months:-59.01%
1 Month:-46.75%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bearish
52-Week Range 0% of range
$0.64 $5.89
Trend Signals
  • Price vs 50-DMABelow
  • Price vs 200-DMABelow
  • RSI (14)25.72 · Oversold
Price Performance
1M-46.75%
3M-59.01%
6M-58.08%
1Y-87.90%

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

No notable strengths flagged.

CONS

  • Trading 89.0% below its 52-week high.
  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
-1.71
Industry PE
25.45
Forward P/E
-2.36
PEG Ratio
-
Book Value
$0.63
Price to Book
1.46
P/S
-
EV/EBITDA
-0.54
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
-
Profit 5Y
-
Revenue (YoY)
-
Earnings (YoY)
-

Profitability & Returns

ROCE
-79.69%
ROE
-49.48%
ROA
-22.70%
Profit Margin
0.00%
Op Margin
0.00%
Gross Margin
0.00%
EPS (Latest Qtr)
$-0.09
EPS (TTM)
$-0.38

Balance Sheet & Liquidity

Debt/Equity
0.38
Quick Ratio
4.67
Current Ratio
4.91
Debt
$143.45K
Total Assets
$47.54M
Current Assets
$66.27M
Working Capital
$43.97M

Ownership

Promoter Holding
3.60%
Chg in Prom Hold
-
FII / Inst Holding
61.54%
Chg in FII Hold
-0.05%

Financial Snapshot

Enterprise Value
$39.21M
Total Revenue (TTM)
$0
EBITDA
$-23.80M
Free Cash Flow
$-15.62M
Operating Cash Flow
$-22.02M
Shares Outstanding
60.33M
Gross Margin
0.00%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 ALDX Aldeyra Therapeutics, Inc. R2KPHARMA 0.65 -1.71 $39.21M 0.00% -79.69% -49.48% - -
2 LLY Eli Lilly and Company SPXR3KPHARMA 1,273.46 42.83 $1.14T 0.60% - 102.29% 7.20% 11.41%
3 JNJ Johnson & Johnson SPXR3KPHARMA 263.81 30.60 $635.76B 1.98% 14.88% 25.74% 2.43% 4.76%
4 ABBV AbbVie Inc. SPXR3KPHARMA 285.64 80.69 $504.76B 2.54% 10.47% -129.24% 1.75% -29.06%
5 UNH UnitedHealth Group Incorporated SPXR3KPHARMA 418.09 26.85 $375.28B 2.47% 9.74% 14.15% 10.40% 5.43%
6 MRK Merck & Co., Inc. SPXR3KPHARMA 145.27 116.22 $358.41B 2.31% - 6.96% 5.64% 10.01%
7 NVS Novartis AG PHARMA 151.12 22.83 $287.24B 3.36% 21.09% 30.35% 9.25% 26.22%
8 AZN AstraZeneca PLC NDXPHARMA 171.49 25.63 $265.96B 2.00% 15.97% 21.96% 9.82% 45.96%
9 TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA 673.82 36.30 $249.14B 0.29% 8.14% 13.51% 8.81% 12.95%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Sep 2013Mar 2014Jun 2014Sep 2014Mar 2015Jun 2015Sep 2015Mar 2016Jun 2016Sep 2016Mar 2017Jun 2017Sep 2017Mar 2018Jun 2018Sep 2018Mar 2019Jun 2019Sep 2019Mar 2020Jun 2020Sep 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Revenue ----------------------------------00000-
Cost of Revenue ----------------------------------------
Gross Profit ----------------------------------------
Operating Expenses ----------------------------------10.43M10.17M8.00M6.67M3.55M-
Operating Income -1.17M-1.24M-1.65M-1.97M-2.11M-2.20M-3.34M-4.97M-4.30M-4.78M-5.10M-5.33M-5.02M-8.49M-9.17M-10.95M-17.43M-13.73M-19.02M-9.64M-7.11M-8.39M-10.83M-14.54M-15.44M-16.48M-17.71M-14.78M-16.80M-10.34M-9.55M-9.39M-18.01M--10.43M-10.17M-8.00M-6.67M-3.55M-5.85M
EBITDA -----------------------------------9.39M-9.23M-7.15M-5.92M-2.92M-
Interest Expense ----------------------------------483.53K470.62K475.90K475.26K468.68K-
Pretax Income -----------------------------------9.93M-9.77M-7.69M-6.46M-3.45M-
Tax Provision ----------------------------------------
Net Income 9.31M401.77K-1.14M-2.01M-2.14M-2.23M-3.37M-4.97M-4.30M-4.78M-5.09M-5.31M-4.99M-8.40M-9.05M-10.81M-15.62M-13.33M-18.72M-9.87M-7.52M-8.87M-11.29M-14.94M-15.79M-16.79M-17.78M-14.55M-15.62M-8.99M-8.19M-8.08M-16.85M--9.93M-9.77M-7.69M-6.46M-3.45M-5.45M
Diluted EPS -9.81-4.04-1.56-0.36-0.32-0.27-0.35-0.51----------------0.28-0.27-0.29-0.30-0.25-0.27-0.15-0.14-0.14-0.28-0.25-0.17-0.16-0.13--0.06-0.09
R&D Expense 666.04K444.28K663.91K1.20M1.14M1.25M2.08M3.51M2.83M3.38M3.37M3.85M3.54M6.60M6.79M7.88M7.85M10.66M16.22M6.63M4.89M6.13M7.73M11.47M12.89M12.23M14.57M11.54M11.24M6.96M6.96M6.18M14.97M12.44M7.42M8.51M5.43M-2.41M3.48M

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue ---------0000
Cost of Revenue -------------
Gross Profit -------------
Operating Expenses ---------62.68M42.79M60.12M35.27M
Operating Income -3.68M-7.27M-11.99M-18.70M-22.49M-39.70M-63.07M-36.42M--62.68M-42.79M-60.12M-35.27M
EBITDA ----------60.07M-35.21M-53.68M-31.69M
Interest Expense ---------1.69M2.07M1.93M1.91M
Pretax Income ----------62.02M-37.54M-55.85M-33.85M
Tax Provision --------0----
Net Income 13.06M-5.19M-12.09M-18.70M-22.34M-38.89M-60.83M-37.55M--62.02M-37.54M-55.85M-33.85M
Diluted EPS -17.61-3.09-1.40-------1.06-0.64-0.94-0.56
R&D Expense 1.54M3.71M7.57M13.18M16.30M29.82M44.35M24.68M44.94M47.31M29.46M48.22M25.66M

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2012Dec 2013Dec 2014Dec 2015Jan 2016Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets -3.74M8.79M28.20M-25.19M44.17M95.09M75.52M83.35M-181.29M148.33M104.61M72.06M
Current Assets -----------181.02M147.81M104.07M71.78M
Cash & Equivalents 1.22M3.26M8.53M14.65M14.65M12.02M20.02M47.36M44.43M77.86M-144.42M142.82M54.53M70.04M
Inventory ---------------
Receivables ----------28.77K3.24M0--
Total Liabilities -5.65M2.50M3.33M-3.54M4.57M8.47M27.44M23.84M-30.28M28.53M33.60M27.81M
Current Liabilities -605.01K1.33M2.12M-2.30M3.35M8.47M12.91M12.41M-15.36M22.26M18.60M27.81M
Long Term Debt -1.13M1.18M1.21M-1.24M1.22M-14.53M11.43M15.50M14.92M-15.00M-
Total Debt -----------16.08M15.66M15.30M15.53M
Total Equity -54.38M-40.22M6.28M24.88M24.88M21.65M39.60M86.62M48.08M59.51M-151.01M119.80M71.00M44.25M
Shares Outstanding -----------58.56M59.20M59.65M60.16M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow ----19.22M-29.86M-44.98M-37.49M--56.64M-30.33M-43.21M-33.35M
Investing Cash Flow ----10.20M-23.34M18.48M29.02M--29.95M30.00M-44.92M47.74M
Financing Cash Flow ---37.43M80.53M23.58M41.90M-1.22M-1.27M-171.42K1.12M
Capital Expenditure -14.06K-86.12K-11.81K-24.76K-262.97K-9.53K--7.81K-16.32K---
Free Cash Flow ----19.25M-30.12M-44.99M---56.65M-30.33M-43.21M-33.35M
Net Change in Cash ---------85.37M-1.60M-88.30M15.51M

Ratios (Annual)

Figures in %.

Metric Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % -------------
Operating Margin % -------------
Net Margin % -------------
ROE % -32.5%-82.5%-48.6%-86.4%-56.4%-44.9%-126.5%-63.1%--41.1%-31.3%-78.7%-76.5%
ROCE % -117.1%-97.5%-46.0%-81.7%-55.1%-45.8%-100.7%-51.3%--37.8%-33.9%-69.9%-79.7%

Shareholding Pattern

Insiders
3.60%
Institutions
61.54%
Public Float
63.84%

Top Institutional Holders

#Holder% HeldSharesValue
1 Knoll Capital Management, LLC 9.08% 5.48M $5.02M
2 AQR Capital Management, LLC 6.22% 3.75M $3.44M
3 Kingdon Capital Management LLC 4.40% 2.65M $2.43M
4 Vanguard Capital Management LLC 3.92% 2.36M $2.16M
5 Shaw D.E. & Co., Inc. 3.22% 1.94M $1.78M
6 Marshall Wace LLP 2.50% 1.51M $1.38M
7 683 Capital Management LLC 2.40% 1.45M $1.33M
8 Jane Street Group, LLC 2.28% 1.38M $1.26M
9 Blackrock Inc. 2.08% 1.26M $1.15M
10 Qube Research & Technologies Ltd 1.87% 1.13M $1.03M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for ALDX

Yahoo Finance ue, 29 Sep 2026

Aldeyra to Appeal FDA Rejection of Reproxalap for Dry Eye Disease

Aldeyra Therapeutics (NASDAQ:ALDX) said it plans to submit a formal dispute resolution request, or FDRR, to the FDA’s Office of New Drugs seeking review of the agency’s latest complete response letter for reproxalap, its investigational tre…

Yahoo Finance ue, 29 Sep 2026

Aldeyra Therapeutics Plans Formal FDA Dispute Resolution Request for Reproxalap After Third Complete Response Letter

Aldeyra Therapeutics intends to formally challenge the FDA’s March 2026 rejection of reproxalap for dry eye disease, with a Formal Dispute Resolution Request and meeting with the agency’s Office of New Drugs expected in the fourth quarter o…

Yahoo Finance ue, 29 Sep 2026

Aldeyra Therapeutics Announces Intent to Submit Formal Dispute Resolution Request for Reproxalap to Treat Dry Eye Disease

CONCORD, Mass., September 29, 2026--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced intent t…

Yahoo Finance hu, 15 Oct 2026

RARE's Fayuvi Approval Spurs Second PRV Sale Worth $203M in a Week

Ultragenyx agrees to sell its Fayuvi-linked PRV for $203 million, marking its second voucher sale in one week and adding non-dilutive funding for rare-disease programs.

Yahoo Finance Wed, 14 Oct 2026

Here's Why You Should Add ANRO Stock to Your Portfolio Now

Alto advances its depression drug pipeline, with key 2027 study results ahead for ALTO-207, ALTO-300 and ALTO-100.

Yahoo Finance Wed, 14 Oct 2026

Syndax Stock Falls 16% as Phase II Fibrosis Study Misses Primary Goal

SNDX shares plunge 16% as its phase II axatilimab study misses the primary endpoint, prompting the company to abandon development in idiopathic pulmonary fibrosis.

ALDX — Frequently Asked Questions

What is the current share price of Aldeyra Therapeutics, Inc. (ALDX)?

As of 2026-10-23 16:27 PDT, Aldeyra Therapeutics, Inc. (ALDX) trades at $0.65 on NasdaqCM. Its 52-week range is $0.64 to $5.89.

What is the market capitalisation of ALDX?

Aldeyra Therapeutics, Inc. (ALDX) has a market capitalisation of $39.21M on NasdaqCM.

What is the P/E ratio of ALDX?

ALDX trades at a trailing price-to-earnings (P/E) ratio of -1.71. The industry average P/E is 25.45. Its price-to-book (P/B) ratio is 1.46.

What is the return on equity (ROE) of ALDX?

ALDX has a return on equity (ROE) of -49.48%. Its return on capital employed (ROCE) is -79.69%.

Is ALDX a good stock to buy?

This page provides a data-driven analysis of Aldeyra Therapeutics, Inc. (ALDX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space